Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Pliant Therapeutics (PLRX)
NASDAQ:PLRX
Holding PLRX?
Track your performance easily
PLRX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$10.22 - $19.62
Previous Close$13.3
Volume386.98K
Average Volume (3M)456.11K
Market Cap
$809.35M
Enterprise Value$465.05M
Total Cash (Recent Filing)$404.51M
Total Debt (Recent Filing)$60.21M
Price to Earnings (P/E)―
Beta1.66
Next Earnings
Mar 04, 2025EPS Estimate
-$0.99Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.34
Shares Outstanding60,853,623
10 Day Avg. Volume406,386
30 Day Avg. Volume456,112
Standard Deviation0.26
R-Squared0.04
Alpha-0.00499
Financial Highlights & Ratios
Price to Book (P/B)2.42
Price to Sales (P/S)512.25
Price to Cash Flow (P/CF)-6.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit294.34
Enterprise Value/Ebitda-2.41
Forecast
1Y Price Target
$39.25Price Target Upside186.08% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Pliant Therapeutics News
PremiumCompany Announcements
Pliant Therapeutics Reports Increased Losses and Strategic Focus
Bulls Say, Bears Say
Bulls Say
Clinical DataPositive data from a prior Phase 2a study and other studies have shown the anti-fibrotic properties and potential of bexotegrast in lung remodeling, building confidence in its success.
Clinical DevelopmentThe modification of the BEACON-IPF trial into a pivotal, adaptive Phase 2b/3 trial has been accepted by global health agencies, enhancing the trial's potential for registration.
Financial PositionThe company has a cash reserve of $406 million, providing an operational expense runway through the second half of 2026.
Bears Say
Financial PerformanceThe company reported a net loss driven by increased operating expenses, primarily due to costs associated with the BEACON-IPF program.
Market CatalystsThere are no stock moving catalysts expected in the interim before mid-2026.
Stock MovementThe timeline to data from the Phase 2b BEACON-IPF study may constrain stock movement over the near term.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
PLRX FAQ
What was Pliant Therapeutics’s price range in the past 12 months?
Pliant Therapeutics lowest stock price was $10.22 and its highest was $19.62 in the past 12 months.
What is Pliant Therapeutics’s market cap?
Currently, no data Available
When is Pliant Therapeutics’s upcoming earnings report date?
Pliant Therapeutics’s upcoming earnings report date is Mar 04, 2025 which is in 73 days.
How were Pliant Therapeutics’s earnings last quarter?
Pliant Therapeutics released its earnings results on Nov 07, 2024. The company reported -$0.95 earnings per share for the quarter, beating the consensus estimate of -$0.969 by $0.019.
Is Pliant Therapeutics overvalued?
According to Wall Street analysts Pliant Therapeutics’s price is currently Undervalued.
Does Pliant Therapeutics pay dividends?
Pliant Therapeutics does not currently pay dividends.
What is Pliant Therapeutics’s EPS estimate?
Pliant Therapeutics’s EPS estimate is -$0.99.
How many shares outstanding does Pliant Therapeutics have?
Pliant Therapeutics has 60,853,622 shares outstanding.
What happened to Pliant Therapeutics’s price movement after its last earnings report?
Pliant Therapeutics reported an EPS of -$0.95 in its last earnings report, beating expectations of -$0.969. Following the earnings report the stock price went down -1.251%.
Which hedge fund is a major shareholder of Pliant Therapeutics?
Among the largest hedge funds holding Pliant Therapeutics’s share is RA Capital Management. It holds Pliant Therapeutics’s shares valued at 14M.
---
Pliant Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$39.25 (186.08% Upside)
$39.25 (186.08% Upside)
Blogger Sentiment
Bullish
PLRX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 11.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 6.1%
Last 30 Days ▼ 6.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-14.30%
12-Months-Change
Fundamentals
Return on Equity
-47.52%
Trailing 12-Months
Asset Growth
-17.54%
Trailing 12-Months
Company Description
Pliant Therapeutics
Pliant Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Its lead product candidate, PLN-74809, is an oral small-molecule dual that helps in the treatment of idiopathic pulmonary fibrosis.
---
PLRX Stock 12 Month Forecast
Average Price Target
$39.25
▲(186.08% Upside)
Technical Analysis
Best Analysts Covering PLRX
1 Year
1 Year Success Rate
10/23 ratings generated profit
1 Year Average Return
+35.60%
reiterated a buy rating last month
Copying Ed Arce's trades and holding each position for 1 Year would result in 43.48% of your transactions generating a profit, with an average return of +35.60% per trade.
---